AU1302899A - Antisense compounds to insulin-like growth factor-1 receptor - Google Patents

Antisense compounds to insulin-like growth factor-1 receptor

Info

Publication number
AU1302899A
AU1302899A AU13028/99A AU1302899A AU1302899A AU 1302899 A AU1302899 A AU 1302899A AU 13028/99 A AU13028/99 A AU 13028/99A AU 1302899 A AU1302899 A AU 1302899A AU 1302899 A AU1302899 A AU 1302899A
Authority
AU
Australia
Prior art keywords
insulin
receptor
growth factor
antisense compounds
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13028/99A
Other languages
English (en)
Inventor
Gerald Zon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of AU1302899A publication Critical patent/AU1302899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU13028/99A 1997-11-04 1998-11-03 Antisense compounds to insulin-like growth factor-1 receptor Abandoned AU1302899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96388697A 1997-11-04 1997-11-04
US08963886 1997-11-04
PCT/US1998/023418 WO1999023259A1 (fr) 1997-11-04 1998-11-03 Composes antisens du recepteur du facteur de croissance de substances apparentees a l'insuline 1

Publications (1)

Publication Number Publication Date
AU1302899A true AU1302899A (en) 1999-05-24

Family

ID=25507861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13028/99A Abandoned AU1302899A (en) 1997-11-04 1998-11-03 Antisense compounds to insulin-like growth factor-1 receptor

Country Status (2)

Country Link
AU (1) AU1302899A (fr)
WO (1) WO1999023259A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
WO2000009145A1 (fr) * 1998-08-13 2000-02-24 Thomas Jefferson University Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i
CA2515484C (fr) * 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation de l'expression du recepteur du facteur de croissance i analogue a l'insuline
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08508405A (ja) * 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法

Also Published As

Publication number Publication date
WO1999023259A1 (fr) 1999-05-14

Similar Documents

Publication Publication Date Title
EP1175213A4 (fr) Composes heterocycliques aromatiques utilises comme secretagogues d'hormones de croissance
AU4580599A (en) Stable no-delivering compounds
IL136824A0 (en) Crystalline teriparatide
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU5835198A (en) Fishing reel
IL143834A0 (en) Insulin-like growth factor (igf) i mutant variants
AU6895698A (en) Growth of basrtio3 using polyamine-based precursors
AU6700798A (en) Fishing reel
AU6154398A (en) Stable microemulsion cleaning composition
HK1044768A1 (zh) 晶狀1-甲基碳青霉烯化合物
AU4567199A (en) Autoinducer compounds
IL147253A0 (en) Growth hormone formulations
AU7906998A (en) Compounds with growth hormone releasing properties
AU5671099A (en) Compounds having growth hormone releasing activity
AU1302899A (en) Antisense compounds to insulin-like growth factor-1 receptor
AU1488001A (en) Stabilized thyroxine compounds
AU4634200A (en) Fish feed
AU7018498A (en) Composition comprising plant growth promoting rhizobacteria
IL132618A0 (en) Crystalline roxifiban
AU2686899A (en) Growth hormone secretagogues
AU8145598A (en) Cartilage growth agent
AU6450696A (en) Growth factor receptor-binding insulin receptor
AUPO937897A0 (en) Fishing line sinker
AU1321797A (en) A growth promoting substance
GB9916252D0 (en) Growth hormone formulation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase